This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive stem cell transplantation (SCT) despite medical eligibility. Complete response (CR)/unconfirmed CR (CRu) rates were 67 vs. 39% (odds ratio 3.69 [95% CI(confidence interval): 1.31, 10.41]; p = .012). After 40 months median follow-up, median progression-free survival by independent radiology committee with VR-CAP vs. R-CHOP was 32.6 vs. 12.0 months (hazard ratio (HR) 0.59 [95% CI: 0.31, 1.13]; p = .108); median overall survival was not reached vs. 47.3 months (HR 0.81 [95% CI: 0.33, 1.96]; p = .634). Adverse events included neutropenia (92/76%), thrombocytopenia (70/10%) and leukopenia (65/50%). VR-CAP represents a potential alternative to R-CHOP in combined and/or alternating regimens for younger, SCT-eligible MCL patients.

b Sun Yat sen University Cancer Center Guangzhou Guangdong China

c Nizhniy Novgorod Region Clinical Hospital Nizhniy Novgorod Russian Federation

e Carol G Simon Cancer Center Morristown NJ USA

f CHU Dinant Godinne UCL Namur Yvoir Belgium

g Charles University Prague Prague Czech Republic

h Gdynia Oncology Center and Medical University of Gdansk Gdynia Poland

i Institutul Regional de Oncologie Iasi Judetul lasi Romania

j King Chulalongkorn Memorial Hospital Chulalongkorn University Bangkok Thailand

Janssen Research and Development LLC Raritan NJ USA

k Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine Lviv Ukraine

l Institute of Urgent and Recovery Surgery n a 5 K Gusaka of AMS of Ukraine Donetsk Ukraine

m Medical University of Lodz Copernicus Memorial Hospital Lodz Poland

Medical University of Vienna Vienna General Hospital Vienna Austria

o Janssen Research and Development High Wycombe United Kingdom

p Millennium Pharmaceuticals Inc Boston MA USA

q Oncology Institute of Southern Switzerland Ospedale San Giovanni Bellinzona Switzerland

University of Alberta Cross Cancer Institute Edmonton AB Canada

000      

00000naa a2200000 a 4500

001      

bmc19012912

003      

CZ-PrNML

005      

20190412121605.0

007      

ta

008      

190405s2018 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1080/10428194.2017.1365855 $2 doi

035    __

$a (PubMed)29338540

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Drach, Johannes $u a Medical University of Vienna, Vienna General Hospital , Vienna , Austria.

245    10

$a Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study / $c J. Drach, H. Huang, O. Samoilova, A. Belch, C. Farber, A. Bosly, J. Novak, J. Zaucha, A. Dascalescu, U. Bunworasate, Z. Masliak, K. Vilchevskaya, T. Robak, L. Pei, B. Rooney, H. van de Velde, F. Cavalli,

520    9_

$a This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive stem cell transplantation (SCT) despite medical eligibility. Complete response (CR)/unconfirmed CR (CRu) rates were 67 vs. 39% (odds ratio 3.69 [95% CI(confidence interval): 1.31, 10.41]; p = .012). After 40 months median follow-up, median progression-free survival by independent radiology committee with VR-CAP vs. R-CHOP was 32.6 vs. 12.0 months (hazard ratio (HR) 0.59 [95% CI: 0.31, 1.13]; p = .108); median overall survival was not reached vs. 47.3 months (HR 0.81 [95% CI: 0.33, 1.96]; p = .634). Adverse events included neutropenia (92/76%), thrombocytopenia (70/10%) and leukopenia (65/50%). VR-CAP represents a potential alternative to R-CHOP in combined and/or alternating regimens for younger, SCT-eligible MCL patients.

650    _2

$a dospělí $7 D000328

650    _2

$a věkové faktory $7 D000367

650    _2

$a myší monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D058846

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971

650    _2

$a bortezomib $x škodlivé účinky $x terapeutické užití $7 D000069286

650    _2

$a cyklofosfamid $x škodlivé účinky $x terapeutické užití $7 D003520

650    _2

$a doxorubicin $x škodlivé účinky $x terapeutické užití $7 D004317

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a lidé $7 D006801

650    _2

$a leukopenie $x chemicky indukované $x epidemiologie $7 D007970

650    _2

$a lymfom z plášťových buněk $x mortalita $x terapie $7 D020522

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a neutropenie $x chemicky indukované $x epidemiologie $7 D009503

650    _2

$a směrnice pro lékařskou praxi jako téma $7 D017410

650    _2

$a prednison $x škodlivé účinky $x terapeutické užití $7 D011241

650    _2

$a doba přežití bez progrese choroby $7 D000077982

650    _2

$a rituximab $x škodlivé účinky $x terapeutické užití $7 D000069283

650    _2

$a transplantace kmenových buněk $x normy $7 D033581

650    _2

$a trombocytopenie $x chemicky indukované $x epidemiologie $7 D013921

650    _2

$a výsledek terapie $7 D016896

650    _2

$a vinkristin $x škodlivé účinky $x terapeutické užití $7 D014750

655    _2

$a klinické zkoušky, fáze III $7 D017428

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Huang, Huiqiang $u b Sun Yat-sen University Cancer Center , Guangzhou , Guangdong , China.

700    1_

$a Samoilova, Olga $u c Nizhniy Novgorod Region Clinical Hospital , Nizhniy Novgorod , Russian Federation.

700    1_

$a Belch, Andrew $u d University of Alberta, Cross Cancer Institute , Edmonton , AB , Canada.

700    1_

$a Farber, Charles $u e Carol G. Simon Cancer Center , Morristown , NJ , USA.

700    1_

$a Bosly, André $u f CHU Dinant-Godinne UCL Namur , Yvoir , Belgium.

700    1_

$a Novak, Jan $u g Charles University in Prague , Prague , Czech Republic.

700    1_

$a Zaucha, Jan $u h Gdynia Oncology Center & Medical University of Gdansk , Gdynia , Poland.

700    1_

$a Dascalescu, Angela $u i Institutul Regional de Oncologie Iasi , Judetul, lasi , Romania.

700    1_

$a Bunworasate, Udomsak $u j King Chulalongkorn Memorial Hospital , Chulalongkorn University , Bangkok , Thailand.

700    1_

$a Masliak, Zvenyslava $u k Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine , Lviv , Ukraine.

700    1_

$a Vilchevskaya, Kateryna $u l Institute of Urgent and Recovery Surgery n.a V.K. Gusaka of AMS of Ukraine , Donetsk , Ukraine.

700    1_

$a Robak, Tadeusz $u m Medical University of Lodz, Copernicus Memorial Hospital , Lodz , Poland.

700    1_

$a Pei, Lixia $u n Janssen Research & Development, LLC , Raritan , NJ , USA.

700    1_

$a Rooney, Brendan $u o Janssen Research & Development , High Wycombe , United Kingdom.

700    1_

$a van de Velde, Helgi $u p Millennium Pharmaceuticals, Inc , Boston , MA , USA.

700    1_

$a Cavalli, Franco $u q Oncology Institute of Southern Switzerland Ospedale San Giovanni , Bellinzona , Switzerland.

773    0_

$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 59, č. 4 (2018), s. 896-903

856    41

$u https://pubmed.ncbi.nlm.nih.gov/29338540 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20190405 $b ABA008

991    __

$a 20190412121624 $b ABA008

999    __

$a ok $b bmc $g 1392222 $s 1051217

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2018 $b 59 $c 4 $d 896-903 $e 20180117 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140

LZP    __

$a Pubmed-20190405